Triamcinolone Levels in Cochlear Perilymph

Status Completed

Clinical Trial Summary

In this study Triamcinolone acetonide will be applied intratympanically before cochlear implant surgery. After round window exposure, a perilymph sample and simultaneously a blood sample will be drawn. Triamcinolone levels will then be analyzed in the samples.

Clinical Trial Description

At the ENT department of the university hospital Vienna (AKH Wien) patients are treated with intratympanic triamcinolone acetonide before cochlea implantation to reduce inflammation and in some cases to protect residual hearing. Triamcinolone acetonide levels in cochlear perilymph will be evaluated in an open prospective clinical study. Patients scheduled for cochlear implant surgery between 18 and 90 years will be included. Patients who are treated with steroids preoperatively will be excluded from the study. Patients will be randomized after inclusion to one of four groups. The randomization is carried out to generate hypothesis for the needed dose and best time of application in the future. Triamcinolone acetonide will then be applied 20-24h before surgery or at the beginning of the surgery, depending on randomization (see below). About 20 µl of perilymph will be sampled simultaneously to a blood sample during cochlear implant surgery. The probes will be stored at -80°C. Triamcinolone acetonide levels of the blood and perilymph will be determined by the pharmaceutical laboratory (Department of Pharmaceutical Technology and Biopharmaceutics, University of Vienna). The patients will be randomized to 4 groups. Group 1 - Volon A 10mg administration 20 - 24 hours before sampling. Group 2 - Volon A 40mg administration 20 - 24 hours before sampling. Group 3 Volon A 10mg - administration 1 to 2 hours before sampling. Group 4 - Volon A 40mg administration 1 to 2 hours before sampling. The time interval of application (1 to 2 hours and 20 to 24 hours before sampling) are a result of varying time of surgery depending on surgeons and patient anatomy as well as day to day clinical organization. Patients can withdraw consent at any time of the study. The active phase of each patient will be between 6 and 9 days depending on time of follow-up visit. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03248856
Study type	Interventional
Source	Medical University of Vienna
Contact
Status	Completed
Phase	Phase 1
Start date	October 2, 2017
Completion date	May 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03212924` - Listening Effort in Cochlear Implant Users	N/A
Withdrawn	`NCT04041596` - Degree of Benefit From Low-Frequency Acoustic Amplification Using the Advanced Bionics Acoustic Earhook	Phase 4
Recruiting	`NCT04610112` - PMCF on Safety and Performance of HiResTM Ultra/Ultra 3D Cl Mid-Scala Electrodes in Adults With Severe-to-profound Hearing Loss
Recruiting	`NCT04610216` - Investigation of the Automatic Technology on the Naída M Hearing Devices
Completed	`NCT03288753` - Comparison Between Neuro 1 and Neuro 2 Cochlear Implant Speech Processors	N/A
Completed	`NCT04048239` - Development of a Robotic Minimally Invasive Pathway for Cochlear Implantation	N/A
Completed	`NCT04815343` - Investigation of the Naída CI M90 Sound Processor in Various Acoustic Scenarios	N/A
Completed	`NCT04145661` - Non-linear Frequency Compared to Conventional Processing in Patients With and Without Cochlear Dead Regions.	N/A
Recruiting	`NCT06114680` - Evaluation of the CochSyn Test Prototype to Measure Cochlear Synaptopathy	N/A
Completed	`NCT03756337` - Neuro 1 vs. Neuro 2 Sound Processors	N/A
Completed	`NCT04120181` - A New Predictor Marker for Cochlear Implants Infection
Terminated	`NCT05586555` - A Monocentric Study Evaluating Pupillometry as an Objective Measurement for CI Fittings	N/A
Recruiting	`NCT04929470` - Safety and Performance of Ultra/Ultra 3D Cl With HiFocus SlimJ Electrode in Adults With Severe-to-profound Hearing Loss
Completed	`NCT04183348` - Evaluation of the Effect of a Visio-Hearing Training Protocol on Spatial Hearing in Subjects With Hearing Loss	N/A
Completed	`NCT06235073` - Robotic and Manual Cochlear Implantation: An Intra-individual Study of Speech Recognition and Electrode Holder Position (ICRobMan)
Recruiting	`NCT05486637` - Vocal Emotion Communication With Cochlear Implants	Early Phase 1
Recruiting	`NCT06301568` - Retrospective Analysis of Long-term Speech Performance in Cochlear Implant Recipients Using Electro-acoustic Stimulation
Recruiting	`NCT06301581` - Retrospective Analysis of Speech Performance Using the HiRes Ultra and HiRes Ultra 3D Cochlear Implant
Withdrawn	`NCT04651660` - Using Electrocochleography During Cochlear Implantation of the Neuro Zti.	N/A
Recruiting	`NCT05709431` - A Study Evaluating the French Version of the CIQoL-35 Quality of Life Questionnaire in Adult Cochlear Implant Use.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.